Successful share issue
The funds will be used to advance the companies relations with dental implants companies, and enable collaborations in order to finalize the product.
The clinical study on the Zolidd prototype presented earlier this year has visualized the potential of the Zolidd technology and further improved the presupposition for Addbio in the dental implants business.
”It’s great that the value of Addbio is recognized. With new funding, and the convincing clinical data presented earlier this year, we find ourselves in a strong position, and look much forward to the next period,” says Dr. Trine Vikinge, AddBIO CEO.